8/31/2016 | PP | Hemispherx negotiates $5 million registered direct offering of units
|
12/16/2015 | PP | Hemispherx to sell stock through $7.94 million at-the-market agreement
|
8/5/2015 | PP | Hemispherx registers $27.67 million of stock for at-the-market sales
|
3/6/2015 | PP | Hemispherx may raise $75 million through at-the-market stock offering
|
3/10/2014 | PP | Jury: Hemispherx lawsuit concerning private stock sale has no merit
|
12/23/2013 | PP | Hemispherx marks 90 million shares for $75 million at-the-market sale
|
10/5/2012 | PP | Hemispherx secures $75 million through at-the-market stock offering
|
9/14/2012 | PP | Hemispherx announces $75 million at-the-market offering of stock
|
7/23/2012 | PP | Hemispherx announces $75 million at-the-market offering of stock
|
6/19/2012 | CVHYPF | Hemispherx files $150 million shelf covering preferreds, stock, debt
|
5/28/2010 | PP | Hemispherx Biopharma arranges equity distribution agreement with Maxim
|
6/9/2009 | CVHY | Hemispherx files $150 million shelf registration covering stock, debt
|
5/19/2009 | PP | Market Commentary: Hemispherx arranges offering; Cytokinetics to raise $14 million; Ondine plans equity exchange
|
5/19/2009 | PP | New Issue: Hemispherx Biopharma negotiates $16 million registered offering of stock, warrants
|
5/11/2009 | PP | New Issue: Hemispherx Biopharma plans $18.3 million registered offering of stock, warrants
|
5/11/2009 | PP | Market Commentary: Redzone plans unit sale; Hemispherx to take in $18.3 million; Petrel wraps £1.84 million deal
|
7/8/2008 | PP | New Issue: Hemispherx secures $30 million from equity line with Fusion Capital
|
6/17/2008 | CV | Hemispherx files $50 million shelf registration
|
7/2/2007 | PP | Hemispherx Biopharma retires all outstanding convertible debentures
|
9/1/2006 | BT | Market Commentary: Sanofi flu news pushes smaller biotechs lower; BioDelivery off 10%; Curis slips on R&D shift
|
8/29/2006 | BT | Hemispherx acquires patent estate from Vanderbilt to create new vaccine technology platform
|
8/29/2006 | BT | Market Commentary: Teva lower; Endo, Penwest up; StemCells gains 7%; Nastech higher; Hemispherx rises 11%
|
8/1/2006 | BT | Hemispherx Biopharma buys royalty interest for Alferon N Injection from Stem Cell Innovations
|
7/27/2006 | BT | Hemispherx regains Amex compliance
|
6/12/2006 | BT | Hemispherx advances flu vaccine trials
|
5/24/2006 | BT | Market Commentary: Sirna, Minrad, AngioDynamics follow-on deals get off; bird flu vaccine names continue to climb
|
5/23/2006 | BT | Market Commentary: Sirna slides 8% ahead of reduced deal; Auxilium gains; Alnylam off; bird flu names up after hours
|
5/15/2006 | BT | Hemispherx starts phase 2 flu trial with Ampligen
|
5/12/2006 | BT | Amex grants extensions for Hemispherx to file 10-K, 10-Q
|
5/3/2006 | BT | Hemispherx says Ampligen shows significant improvements among fatigue patients
|
4/25/2006 | BT | Hemispherx Biopharma preps for NDA filing with addition of scientists, executives
|
4/13/2006 | BT | Market Commentary: Adolor ends better but off highs; ArQule off amid internal changes; Hemispherx spikes 7% on PIPE
|
4/13/2006 | PP | Market Commentary: U.S. Energy secures $50 million equity line; Katanga Mining prices C$101.5 million PIPE
|
4/12/2006 | BTPP | New Issue: Hemispherx Biopharma gets $50 million equity line
|
4/12/2006 | PP | Market Commentary: Hemispherx obtains $50 million equity line; Palatin Technologies will close $26.84 million unit sale
|
4/7/2006 | BT | Hemispherx receives non-compliance notice from Amex
|
3/21/2006 | BT | Market Commentary: Novavax, Nastech buck uptrend in flu names; NitroMed exec exits applauded; BioMarin off on deals
|
3/16/2006 | BT | Hemispherx's Alferon LDO boosts efficacy of flu vaccines, study says
|
2/16/2006 | BT | Hemispherx Biopharma's Ampligen and Alferon LDO may provide defense against avian flu
|
11/29/2005 | BT | Hemispherx forms flu research agreement with Defense R&D Canada
|
11/16/2005 | BT | Market Commentary: Gilead gains on Roche settlement; AtheroGenics sinks; Amylin rises
|
10/24/2005 | BT | Market Commentary: Roche, Gilead gain on flu talks; niche flu names higher as well; Schering, Wyeth, Pfizer watched
|
7/11/2005 | PP | Market Commentary: Holly Energy raises $45.1 million; volume remains steady as stocks rise, oil dips
|
7/11/2005 | BTPP | New Issue: Hemispherx Biopharma receives equity line for up to $20 million
|